BiVictriX Therapeutics (BVX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 17.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 28.00
  • 52 Week Low: 14.50
  • Currency: UK Pounds
  • Shares Issued: 66.12m
  • Volume: 0
  • Market Cap: £11.57m

BVX Overview

BVX has identified a unique, cancer-restricted antigen fingerprint, absent from healthy cells, which can be exploited to produce cancer selective therapeutics. The Bi-Cygni® technology has been developed to exploit this concept and expedite the development of bispecific therapeutics with an improved therapeutic index. Based on BVX's work to date, these ADCs demonstrate superior potency and tumour selectivity compared to conventional ADCs. The main country of operation is in the UK.

1 Day Chart (02-02-2023)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 1.8  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

BVX Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 n/a (0.51) (1.89)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (2.53) (6.02)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

BVX Company Announcements

BiVictriX reports positive BVX001 preclinical data 31-Jan-2023 07:08 RNS
Holding(s) in Company 24-Jan-2023 16:21 RNS
Holding(s) in Company 19-Jan-2023 11:00 RNS

BVX ShareCast News

Michael Kauffman promoted to BiVictriX board chair 06-Jan-2023 ShareCast
BiVictriX identifies development lead for potent... 07-Dec-2022 ShareCast
BiVictriX upbeat on recent pipeline progress 11-Jul-2022 ShareCast

Latest BVX Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

BVX Market Data

Currency UK Pounds
Share Price 17.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 28.00
52 Week Low 14.50
Volume 0
Shares Issued 66.12m
Market Cap £11.57m

BVX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32.46% below the market average32.46% below the market average32.46% below the market average32.46% below the market average32.46% below the market average
13.79% below the sector average13.79% below the sector average13.79% below the sector average13.79% below the sector average13.79% below the sector average
Price Trend
34.94% below the market average34.94% below the market average34.94% below the market average34.94% below the market average34.94% below the market average
48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average
Income Not Available
Growth Not Available

BVX Dividends

No dividends found

Trades for --2023

Time Volume / Share Price
0 @ 0.000p

BVX Key Personnel

CEO Tiffany Jane Thorn

Top of Page